dromlakhani Serial MRI to evaluate tumor size during pegvisomant therapy
STEP 1 — Gather Information
Obtain baseline pituitary MRI with pituitary protocol (thin slices, contrast if appropriate) and record current IGF-1 level, symptoms, and date of pegvisomant initiation.
STEP 2 — Rule In / Rule Out
Is the patient currently receiving pegvisomant for acromegaly and without MRI contraindications (e.g., non‑MRI‑compatible device)? If yes, proceed to Step 3; if no, this skill does not apply.
STEP 3 — Classify or Stratify
Determine time since pegvisomant start: <6 months, 6 months, 12 months, or >12 months. Schedule MRI at 6 and 12 months after initiation; if size stable at 1 year, repeat yearly.
STEP 4 — Decide
If MRI shows tumor growth ≥2 mm or new progression, consider discontinuing pegvisomant or adding a somatostatin receptor ligand; if size is stable, continue pegvisomant and repeat imaging per the schedule.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on IGF‑1 alone to assess tumor activity; pegvisomant lowers IGF‑1 without suppressing tumor growth. Avoid MRI intervals shorter than 6 months unless symptomatic change occurs. Ensure MRI includes dynamic pituitary sequences to distinguish true growth from flow‑related artifacts.
Concrete Clinical Example
A 48‑year‑old woman with acromegaly started pegvisomant 15 mg daily. Baseline MRI showed a 12 mm macroadenoma abutting the cavernous sinus. At 6‑month MRI size unchanged; at 12‑month MRI unchanged. She continues pegvisomant with yearly MRI surveillance.
Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700